|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Marengo A, Rosso C and Bugianesi E: Liver
cancer: Connections with obesity, fatty liver, and cirrhosis. Annu
Rev Med. 67:103–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoshida Y, Fuchs BC, Bardeesy N, Baumert
TF and Chung RT: Pathogenesis and prevention of hepatitis C
virus-induced hepatocellular carcinoma. J Hepatol. 61 (Suppl
1):S79–S90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alawyia B and Constantinou C:
Hepatocellular carcinoma: A narrative review on current knowledge
and future prospects. Curr Treat Options Oncol. 24:711–724. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khameneh SC, Razi S, Lashanizadegan R,
Akbari S, Sayaf M, Haghani K and Bakhtiyari S: MicroRNA-mediated
metabolic regulation of immune cells in cancer: An updated review.
Front Immunol. 15:14249092024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu X, Li Y, Zhang R, Chen X, Shen J, Yuan
M, Chen Y, Chen M, Liu S, Wu J and Sun Q: Jianpi Yangzheng
decoction suppresses gastric cancer progression via modulating the
miR-448/CLDN18.2 mediated YAP/TAZ signaling. J Ethnopharmacol.
311:1164502023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu H, Zhou X, Ma C, Chang H, Li H, Liu F
and Lu J: Low expression of miR-448 induces EMT and promotes
invasion by regulating ROCK2 in hepatocellular carcinoma. Cell
Physiol Biochem. 36:487–498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin Z, Zhu Y and Liu Y: The role of
miR-448 in cancer progression and its potential therapeutic
applications. J Cancer Res Clin Oncol. 143:679–687. 2017.
|
|
11
|
Jiang X, Zhou Y, Sun AJ and Xue JL: NEAT1
contributes to breast cancer progression through modulating miR-448
and ZEB1. J Cell Physiol. 233:8558–8566. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou Y, Lin F, Wan T, Chen A, Wang H,
Jiang B, Zhao W, Liao S, Wang S, Li G, et al: ZEB1 enhances Warburg
effect to facilitate tumorigenesis and metastasis of HCC by
transcriptionally activating PFKM. Theranostics. 11:5926–5938.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Ouyang F, Gao A, Zeng T, Li M, Li
H, Zhou W, Gao Q, Tang X, Zhang Q, et al: ESM1 enhances fatty acid
synthesis and vascular mimicry in ovarian cancer by utilizing the
PKM2-dependent Warburg effect within the hypoxic tumor
microenvironment. Mol Cancer. 23:942024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jing Z, Liu Q, He X, Jia Z, Xu Z, Yang B
and Liu P: NCAPD3 enhances Warburg effect through c-myc and E2F1
and promotes the occurrence and progression of colorectal cancer. J
Exp Clin Cancer Res. 41:1982022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peng L, Zhao Y, Tan J, Hou J, Jin X, Liu
DX, Huang B and Lu J: PRMT1 promotes Warburg effect by regulating
the PKM2/PKM1 ratio in non-small cell lung cancer. Cell Death Dis.
15:5042024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paul S, Ghosh S and Kumar S: Tumor
glycolysis, an essential sweet tooth of tumor cells. Semin Cancer
Biol. 86:1216–1230. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lan F, Qin Q, Yu H and Yue X: Effect of
glycolysis inhibition by miR-448 on glioma radiosensitivity. J
Neurosurg. 132:1456–1464. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luce A, Lombardi A, Ferri C, Zappavigna S,
Tathode MS, Miles AK, Boocock DJ, Vadakekolathu J, Bocchetti M,
Alfano R, et al: A proteomic approach reveals that miR-423-5p
modulates glucidic and amino acid metabolism in prostate cancer
cells. Int J Mol Sci. 24:6172022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chu M, Zhao Y, Feng Y, Zhang H, Liu J,
Cheng M, Li L, Shen W, Cao H, Li Q and Min L: MicroRNA-126
participates in lipid metabolism in mammary epithelial cells. Mol
Cell Endocrinol. 454:77–86. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guerra F and Bucci C: Role of the RAB7
protein in tumor progression and cisplatin chemoresistance. Cancers
(Basel). 11:10962019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ju L, Luo Y, Cui X, Zhang H, Chen L and
Yao M: CircGPC3 promotes hepatocellular carcinoma progression and
metastasis by sponging miR-578 and regulating RAB7A/PSME3
expression. Sci Rep. 14:76322024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shan Z, Chen X, Chen H and Zhou X:
Investigating the impact of Ras-related protein RAB7A on colon
adenocarcinoma behavior and its clinical significance. Biofactors.
51:e700062025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Q, Bai Y, Shi X, Guo D, Wang Y, Wang
Y, Guo WZ and Zhang S: High RAS-related protein Rab-7a (RAB7A)
expression is a poor prognostic factor in pancreatic
adenocarcinoma. Sci Rep. 12:174922022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Güleç Taşkıran AE, Hüsnügil HH, Soltani
ZE, Oral G, Menemenli NS, Hampel C, Huebner K, Erlenbach-Wuensch K,
Sheraj I, Schneider-Stock R, et al: Post-transcriptional regulation
of Rab7a in lysosomal positioning and drug resistance in
nutrient-limited cancer cells. Traffic. 25:e129562024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang JY, Zhu X, Liu Y and Wu X: The
prognostic biomarker RAB7A promotes growth and metastasis of liver
cancer cells by regulating glycolysis and YAP1 activation. J Cell
Biochem. 125:e306212024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ostrowski M, Carmo NB, Krumeich S, Fanget
I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, et
al: Rab27a and Rab27b control different steps of the exosome
secretion pathway. Nat Cell Biol. 12:19–30. 1–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mulligan RJ and Winckler B: Regulation of
endosomal trafficking by Rab7 and its effectors in neurons: Clues
from charcot-marie-tooth 2B disease. Biomolecules. 13:13992023.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai
W and Guo C: Emerging roles and the regulation of aerobic
glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res.
39:1262020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wen T, Jin C, Facciorusso A, Donadon M,
Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, et al:
Multidisciplinary management of recurrent and metastatic
hepatocellular carcinoma after resection: An international expert
consensus. Hepatobiliary Surg Nutr. 7:353–371. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abdelhamed W and El-Kassas M:
Hepatocellular carcinoma recurrence: Predictors and management.
Liver Res. 7:321–332. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI
|
|
34
|
Shin H and Yu SJ: A concise review of
updated global guidelines for the management of hepatocellular
carcinoma: 2017–2024. J Liver Cancer. 25:19–30. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang F, Hilakivi-Clarke L, Shaha A, Wang
Y, Wang X, Deng Y, Lai J and Kang N: Metabolic reprogramming and
its clinical implication for liver cancer. Hepatology.
78:1602–1624. 2023.PubMed/NCBI
|
|
37
|
Katayama Y, Maeda M, Miyaguchi K, Nemoto
S, Yasen M, Tanaka S, Mizushima H, Fukuoka Y, Arii S and Tanaka H:
Identification of pathogenesis-related microRNAs in hepatocellular
carcinoma by expression profiling. Oncol Lett. 4:817–823. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pegtel DM and Gould SJ: Exosomes. Annu Rev
Biochem. 88:487–514. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li B, Cao Y, Sun M and Feng H: Expression,
regulation, and function of exosome-derived miRNAs in cancer
progression and therapy. FASEB J. 35:e219162021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu X, Tang H, Liu G, Wang H, Shu J and Sun
F: miR-448 suppressed gastric cancer proliferation and invasion by
regulating ADAM10. Tumour Biol. 37:10545–10551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bamodu OA, Huang WC, Lee WH, Wu A, Wang
LS, Hsiao M, Yeh CT and Chao TY: Aberrant KDM5B expression promotes
aggressive breast cancer through MALAT1 overexpression and
downregulation of hsa-miR-448. BMC Cancer. 16:1602016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qi H, Wang H and Pang D: miR-448 promotes
progression of non-small-cell lung cancer via targeting SIRT1. Exp
Ther Med. 18:1907–1913. 2019.PubMed/NCBI
|
|
43
|
Liu Y, Ma J, Wang X, Liu P, Cai C, Han Y,
Zeng S, Feng Z and Shen H: Lipophagy-related gene RAB7A is involved
in immune regulation and malignant progression in hepatocellular
carcinoma. Comput Biol Med. 158:1068622023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xie J, Yan Y, Liu F, Kang H, Xu F, Xiao W,
Wang H and Wang Y: Knockdown of Rab7a suppresses the proliferation,
migration, and xenograft tumor growth of breast cancer cells.
Biosci Rep. 39:BSR201804802019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Abrahamian C, Tang R, Deutsch R, Ouologuem
L, Weiden EM, Kudrina V, Blenninger J, Rilling J, Feldmann C, Kuss
S, et al: Rab7a is an enhancer of TPC2 activity regulating melanoma
progression through modulation of the GSK3β/β-Catenin/MITF-axis.
Nat Commun. 15:100082024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song S, Xie S, Liu X, Li S, Wang L, Jiang
X and Lu D: miR-3200 accelerates the growth of liver cancer cells
by enhancing Rab7A. Noncoding RNA Res. 8:675–685. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Y, Chen X, Yao N, Gong J, Cao Y, Su
X, Feng X and Tao M: MiR-448 suppresses cell proliferation and
glycolysis of hepatocellular carcinoma through inhibiting IGF-1R
expression. J Gastrointest Oncol. 13:355–367. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qi C, Zou L, Wang S, Mao X, Hu Y, Shi J,
Zhang Z and Wu H: Vps34 inhibits hepatocellular carcinoma invasion
by regulating endosome-lysosome trafficking via Rab7-RILP and
Rab11. Cancer Res Treat. 54:182–198. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang CC, Meng GX, Dong ZR and Li T: Role
of Rab GTPases in hepatocellular carcinoma. J Hepatocell Carcinoma.
8:1389–1397. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang X, Chen C, Ling C, Luo S, Xiong Z,
Liu X, Liao C, Xie P, Liu Y, Zhang L, et al: EGFR tyrosine kinase
activity and Rab GTPases coordinate EGFR trafficking to regulate
macrophage activation in sepsis. Cell Death Dis. 13:9342022.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aygun D and Yücel Yılmaz D: From gene to
pathways: Understanding novel Vps51 variant and its cellular
consequences. Int J Mol Sci. 26:57092025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Edinger AL, Cinalli RM and Thompson CB:
Rab7 prevents growth factor-independent survival by inhibiting
cell-autonomous nutrient transporter expression. Dev Cell.
5:571–582. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Deffieu MS, Cesonyte I, Delalande F,
Boncompain G, Dorobantu C, Song E, Lucansky V, Hirschler A,
Cianferani S, Perez F, et al: Rab7-harboring vesicles are carriers
of the transferrin receptor through the biosynthetic secretory
pathway. Sci Adv. 7:eaba78032021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jiang C, He X, Chen X, Huang J, Liu Y,
Zhang J, Chen H, Sui X, Lv X, Zhao X, et al: Lactate accumulation
drives hepatocellular carcinoma metastasis through facilitating
tumor-derived exosome biogenesis by Rab7A lactylation. Cancer Lett.
627:2176362025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fan B, Wang L, Hu T, Zheng L and Wang J:
Exosomal miR-196a-5p secreted by bone marrow mesenchymal stem cells
inhibits ferroptosis and promotes drug resistance of acute myeloid
leukemia. Antioxid Redox Signal. 42:933–953. 2025. View Article : Google Scholar : PubMed/NCBI
|
